Ind-Swift Laboratories Ltd

Ind-Swift Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ind-Swift Laboratories Ltd

₹ 124 1.13%
25 Apr 3:20 p.m.
indswiftlabs.com BSE: 532305 NSE : INDSWFTLAB
About

Incorporated in 1995, Ind-Swift Laboratories Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients(APIs), and Advanced Intermediates, and providing Contract Research and Manufacturing Services (CRAMS). [1]

Key Points

Business Segments
APIs: The Co. manufactures APIs for complex therapies including Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, etc. [1]
CRAMS: The Co. provides Contract Research and Manufacturing Services supporting R&D programs from process development to clinical supplies. Its capabilities include synthetic medicinal chemistry, custom synthesis, process R&D, cGMP manufacturing, analytical development, and regulatory support. [2]
Research & Development: The Co. has an R&D center primarily focused on the development and optimization of new and existing process technologies supporting the manufacturing of APIs. [2]
Impurities: The Co. has impurities for over 25 APIs. The Co’s impurity portfolio is stocked with a wide range of standards for quick and reliable supply. [3]

Website BSE NSE
  • Market Cap ₹ 736 Cr.
  • Current Price ₹ 124
  • High / Low ₹ 138 / 63.4
  • Stock P/E 25.7
  • Book Value ₹ 115
  • Dividend Yield 0.00 %
  • ROCE 13.3 %
  • ROE 9.59 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 1.10 times its book value
  • Company has delivered good profit growth of 21.6% CAGR over last 5 years

Cons

  • Company has a low return on equity of 3.20% over last 3 years.
  • Promoters have pledged 86.8% of their holding.
  • Company has high debtors of 153 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
226 227 250 236 247 307 280 310 313 304 310 290 288
178 185 199 180 194 270 227 251 259 241 250 224 236
Operating Profit 48 42 51 56 52 37 53 59 54 64 60 66 52
OPM % 21% 18% 21% 24% 21% 12% 19% 19% 17% 21% 19% 23% 18%
9 3 6 7 8 21 7 8 8 -16 6 7 7
Interest 26 24 24 24 24 23 24 24 22 22 20 21 21
Depreciation 20 28 14 14 21 82 16 16 15 9 14 13 14
Profit before tax 12 -8 19 25 16 -47 20 26 24 16 32 39 24
Tax % 0% -264% 1% 3% -1% -30% 1% 2% -13% 255% 45% 18% 19%
12 -29 19 24 16 -61 20 25 28 -25 17 32 19
EPS in Rs 1.95 -4.94 3.18 4.14 2.71 -10.40 3.36 4.29 4.65 -4.25 2.92 5.36 3.29
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,409 1,134 965 660 653 716 765 757 780 891 1,039 1,207 1,192
1,231 1,063 906 571 546 610 631 630 635 709 837 978 950
Operating Profit 178 72 59 89 107 106 134 126 144 183 202 229 241
OPM % 13% 6% 6% 13% 16% 15% 18% 17% 19% 21% 19% 19% 20%
33 4 -19 -31 1 15 16 120 33 23 37 7 4
Interest 85 140 117 117 106 88 28 92 107 100 96 92 84
Depreciation 40 54 66 84 85 88 87 104 90 87 131 57 50
Profit before tax 87 -119 -142 -143 -83 -55 36 50 -20 18 13 87 111
Tax % -3% 1% 14% 17% 29% 29% 39% 42% -7% 117% 117% 45%
89 -118 -122 -119 -59 -39 22 29 -21 -3 -2 48 43
EPS in Rs 23.50 -30.02 -29.79 -29.14 -14.33 -8.75 4.85 6.09 -3.59 -0.53 -0.36 8.06 7.32
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 1%
5 Years: 10%
3 Years: 16%
TTM: -1%
Compounded Profit Growth
10 Years: 10%
5 Years: 22%
3 Years: 70%
TTM: 154%
Stock Price CAGR
10 Years: 11%
5 Years: 27%
3 Years: 12%
1 Year: 90%
Return on Equity
10 Years: -3%
5 Years: 0%
3 Years: 3%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 38 39 41 42 42 45 46 48 60 60 60 60 60
Reserves 784 814 684 553 476 486 507 540 581 544 541 622 671
1,013 1,240 1,355 1,413 1,457 1,242 1,083 1,148 1,031 1,005 953 862 802
383 280 258 236 240 364 387 188 198 210 247 280 267
Total Liabilities 2,218 2,374 2,339 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,799
910 1,171 1,174 1,117 1,099 1,042 934 914 843 753 630 587 570
CWIP 294 161 78 113 78 70 69 20 11 19 10 8 8
Investments 19 17 17 18 18 18 18 19 17 36 29 30 30
995 1,025 1,070 997 1,020 1,007 1,002 972 998 1,011 1,131 1,199 1,191
Total Assets 2,218 2,374 2,339 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,799

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
73 -47 0 98 79 96 73 -64 125 135 150 195
-205 -48 0 -35 -29 -31 -17 -12 -9 -10 5 -13
125 66 0 -64 -48 -69 -62 100 -133 -124 -141 -186
Net Cash Flow -7 -29 0 -1 3 -4 -6 23 -17 1 14 -4

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 79 133 168 215 208 182 194 169 186 177 160 153
Inventory Days 161 180 182 312 368 305 291 284 315 301 288 242
Days Payable 83 81 103 120 137 91 118 114 124 111 118 113
Cash Conversion Cycle 157 232 247 407 439 396 367 339 377 367 330 282
Working Capital Days 163 246 277 379 255 110 99 305 313 303 290 267
ROCE % 11% 2% 0% 1% 2% 2% 4% 4% 5% 7% 7% 13%

Shareholding Pattern

Numbers in percentages

56 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
42.00% 42.00% 42.00% 42.00% 42.00% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01%
0.05% 0.01% 0.22% 0.06% 0.00% 0.00% 0.04% 0.00% 0.08% 0.17% 0.31% 0.26%
19.50% 19.49% 19.50% 19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 18.73% 8.03%
38.46% 38.50% 38.29% 38.44% 38.50% 38.51% 38.48% 38.52% 38.44% 38.34% 38.96% 49.72%
No. of Shareholders 21,46625,22524,52825,34224,91024,22624,45623,39722,96225,40524,63322,439

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT